CTRI/2023/08/056205尚未招募4 期
A Prospective, Multi-Centre, Single-Arm, Phase IV Study to Assess the Safety and Efficacy of Teriparatide Injection for the Treatment of â??Men and Postmenopausal Women with Osteoporosis who are at High Risk of Fractureâ?? and â??Men and Women with Osteoporosis Associated with Sustained Systemic Glucocorticoid Therapy who are at Increased Risk for Fractureâ?? - NI
Sun Pharmaceutical Industries Limited (SPIL)0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Common Inclusion Criteria:
- •1.Patients who are willing to provide written informed consent and agree to follow the study specific requirement.
- •2.Patients with a diagnosis of osteoporosis who are at high risk for fracture.
- •3.Patients should have at least 2 vertebrae in the L1 to L4 region and at least one hip joint should be evaluable by DXA at the time of screening.
- •4.Male patients must have had a successful vasectomy or they and their female partners must meet the below inclusion criteria no. 8. No sperm donation is allowed during the study period.
- •Inclusion criteria for Men and Post-menopausal women with Osteoporosis who are at Increased Risk of Fracture:
- •5.Ambulatory men or post-menopausal women patients of age between > 45 to <= 85 years.
- •Inclusion criteria for Men and Women with Osteoporosis associated with Sustained Glucocorticoid Use:
- •6.Ambulatory men or women patients of age >= 18 years.
- •7.Patients must be taking a systemic steroid for at least 3 months prior to screening.
- •8.Women of childbearing potential must have a negative urine pregnancy test before study entry and agree to use highly effective methods of contraception to prevent pregnancy from study entry till at least two weeks after the last dose of the study medication.
排除标准
- •1.Patients with history of secondary osteoporosis.
- •2.Patients having history of metabolic bone diseases other than osteoporosis.
- •3.Patients having hypo/hyperthyroidism.
- •4.Patients with primary hyperparathyroidism.
- •5.Patients with severe vitamin D deficiency at screening. Vitamin D repletion will be permitted and participants may be rescreened once.
- •6.Patients having pre-existing hypercalcemia.
- •7.Patients with history of nephrolithiasis, urolithiasis, or hypercalciuria within 2 years prior to screening.
- •8.Patients who require hospitalization or surgical treatment for osteoporosis as judged by the investigator at time of screening or enrolment.
- •9.Patients with vertebral abnormalities at L1 to L4 that may interfere with the vertebral assessment by DXA.
- •10.Patients with history of hip replacement surgery.
- •11.Patients with significantly impaired hepatic function; multiple transaminase elevation of any magnitude which, in the opinion of the investigator, indicative of significant hepatic impairment as per the investigatorâ??s discretion.
- •12.Patients with unexplained elevations of serum alkaline phosphatase greater than 2 times of ULN, or as per the investigatorâ??s judgement.
- •13.Patients with significantly impaired renal function.
- •14.Patient who have received prior treatment with PTH or parathyroid hormone-related peptide (PTHrP), including abaloparatide.
- •15.Patients who have received previous treatment with bisphosphonates in the last 12 months prior to screening.
- •16.Patients who have received previous treatment with any other drug affecting bone metabolism in the last 3 months prior to screening.
- •17.Patients who are receiving treatment with anticonvulsants that affect Vitamin D metabolism at the time of screening or receiving chronic heparin therapy within the 14 days prior to the screening.
- •18.Patients receiving or intended to receive other unacceptable concomitant medicines.
- •19.Patients with history of any cancer within last 5 years prior to screening.
- •20.Patients with history of osteosarcoma at any time prior to screening.
- •21.Patients who have undergone prior external beam or implant radiation therapy to the skeleton.
- •22.Patients with clinically significant cardiovascular, hepatic, renal, metabolic, hematological, immunological, pulmonary, or gastrointestinal disorders as judged by the investigator.
- •23.Patients with concurrent medical conditions that, in the judgment of the Investigator, might interfere with the conduct of the trial, confounded the interpretation of the trial results, or endangered the patientâ??s well-being.
- •24.Patients with previous history of gastric bypass surgery, or any medical condition that would be expected to affect drug absorption within last 1 year prior to randomization.
- •25.Patient with history of HIV, Hepatitis B and Hepatitis C.
- •26.Patients with history of meeting Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for alcohol or substance abuse or dependence within the 6 months before enrolment.
- •27.Prior participation in any clinical trials, involving experimental or investigational drugs, within 6 months before screening or intended to participate during the study period. Patients who have previously participated in any clinical trial involving a
研究者
相似试验
尚未招募
4 期
Safety and Efficacy of Dienogest Tablets in Management of Pelvic Pain Associated with Endometriosis (abnormal tissue growth lying outside uterus)CTRI/2022/04/041959Sun Pharma Laboratories Limited
尚未招募
4 期
Study to Assess the Safety of Trastuzumab Deruxtecan in Indian Patients with Unresectable or Metastatic Her2- Positive Breast Cancer who have received a Prior Anti- Her2 Based treatment.CTRI/2024/07/070945AstraZeneca Pharma India Ltd
尚未招募
4 期
Effects of Amoxycillin and Potassium Clavulanate Oral Syrup in Children With Respiratory InfectioCTRI/2023/08/056267Sun Pharmaceuticals Industries Limited SPI
尚未招募
4 期
A study of Fixed Dose Combination of Tamsulosin and Tadalafil Capsules to check safety and efficacy in Patients with Benign Prostatic Hyperplasia and Erectile Dysfunction.CTRI/2022/06/043152Sun Pharma Laboratory Limited SP
Unknown
4 期
A study to determine safety and effectiveness of Lidocaine (numbing medication) 2% viscous solutioCTRI/2021/02/030953Dr Reddys Laboratories Ltd386